51d2f3ea830e5_european innovation partnership on active and healthy ageing - a1 web v2.pdf

8/11/2019 51d2f3ea830e5_European Innovation Partnership on Active and Healthy Ageing - A1 web v2.pdf

http://slidepdf.com/reader/full/51d2f3ea830e5european-innovation-partnership-on-active-and-healthy-ageing 1/4

European

Commission

European Innovation

Partnership onActive & Healthy Ageing

“Better prescription andadherence to medical plans

for older patients”

European Innovation

Partnership onActive & Healthy Ageing



What is the European Innovation Partnershipon Active and Healthy Ageing?

The European Innovation Partnership on Active and Healthy Ageing is

a collaborative partnership with EU countries, regions, industry and

professionals aiming to improve older people’s healthy lives. Workingtogether in six thematic Action Groups, the partners are committing

themselves to find and implement innovative solutions that meet the

needs of the ageing population. The ultimate aim is to increase the average

healthy lifespan of EU citizens by 2 years by 2020.

Prescription and adherence to medical plans:an Action Group to deliver results for Europe

This Action Group brings together partners across the European Union from

local to national levels (health and care organisations, academia, industry,

enterprises and public authorities) which are committed to implementing

innovative solutions to improve older people adherence to medical

plans.

Poor adherence to medical plans is indeed a widespread phenomenon,

undermining the patients’ health as well as the effectiveness of therapy, andhas significant implications on the costs sustained by healthcare systems.

The commitments

A Commitment is a set of measurable and concrete activities at local,

regional or national level performed by those stakeholders who have joined

the Partnership. More than 60 commitments of the present Action Group

contribute to a common Action Plan that will deliver progress in improving

older people adherence to health plans, as agreed by the partners.

Concepts

1

The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company

Adherence to treatment: Adherence to treatment is defined as “The

extent to which a patient’s behaviour (in terms of taking medication,

following a diet, changing habits or attending clinics) coincides with

medical or health advice”1.



Our working areas

1. Improve patient adherence to medical plans through, for

instance, IT solutions which monitor the regular intake of drugs.

2. Empower the patients and care givers to take care of their

health and to be independent through, for example, improving

patients ability to understand their health status.

3. Deliver improvements in the health care systems through,

among the others, new organisational models aimed at developing

the competences and the connexion between health professionals.

4. Improve data evidence existing on ageing and adherence, for

instance by investigating the use of databases on prescriptions to

evaluate the effect of prescribed interventions on citizens health.

5. Help to better communicate among different actors in the healing

and caring process.

Success stories from the partners

Î In Spain, self-management by patients is being promoted within

a comprehensive chronicity strategy. Among the different actions,chronic patients and carers are supported to train their peers with

the objective of improving their skills to take better control of their

health. A Personalized Pharmacotherapeutical Plan is included in

the Electronic Prescription tool in the Patient Electronic Health

Record. This information can be directly accessed by the patient

through the Online Personal Health Folder, enhancing long term

adherence to care plans. The overall strategy is expected to result

in 3,000 “activated” chronic patients by end of year 2014.

Î In Spain a Pharmaceutical Care programme by community

pharmacists is being developed to improve adherence to treatment

among the elderly chronic patients. It builds on a pilot conducted in

2010 that showed an increase o adherence to treatment or this

target population rom 41.2% to 70.6% afer structured pharmacist

intervention. Other objectives o this program are to contribute to

the sustainability and efficiency o the health system (e.g. reducing

medicines waste,) and develop new models o communication

between health proessionals and patients, and among health



proessionals. This project will also assess the contribution to adherence by using

innovative IT tools such as, for instance, e-prescriptions, patient’s medication

electronic records, remote warnings and a specific electronic tool to facilitate

monitoring.

ÎIn The Netherlands a society wide Healthy Ageing strategy is deployed. Aspecific action is on analysis of a large pharmacy prescription database with

more than 500,000 patients. Use and outcomes will be determined during

periods of conditional reimbursement and adherence will be measured. In

addition a large project on Health Literacy, involving other European countries,

is on-going: it will develop a comprehensive intervention model for addressing

Health Literacy needs in older adults and formulate guidelines for policy and

practice for health literacy in all EU member states.

Î In Scotland monitoring is taking place in community pharmacies of patientstaking new medicines and high risk drugs which will address adherence issues

and any care issues related to a patient’s medication. This will be available for up

to 1.9 million people in Scotland providing integrating local services provided by

GP’s, pharmacists and other community practioners. Of the patients registered

for the service, 99% of these have care plans that address issues regarding

medication. Through national guidance and risk assessment tools, patients

taking multiple drugs are reviewed with the active involvement of pharmacists

who review medication and follow up patients’ adherence. This will hope to

reduce hospital admissions due to adverse side- effects of medication. A specificguidance document and an electronic monitoring tool are produced in order to

support pharmacist’s action. Factors such as co-morbidities and dementia were

identified as those where the patient may need more support.

For more informationhttps://webgate.ec.europa.eu/eipaha/

@EIP_AHA

[email protected]

51d2f3ea830e5_european innovation partnership on active and healthy ageing - a1 web v2.pdf

Documents